Rallybio (RLYB) news
Recent news
RallyBio Corp - CFO Jonathan Lieber's employment to terminate upon closing of Avenzo business combination - SEC filing
RallyBio Corp (NASDAQ: RYBO) has announced that the employment of Jonathan Lieber, its Chief Financial Officer (CFO), will terminate upon the closing of the company’s business combination with Avenzo Acquisition Corp, a special purpose acquisition company (SPAC). The information was disclosed in a…
AInvest Wire · Sep 9, 2026RallyBio Corp - Jonathan Lieber to remain as RallyBio CFO and principal financial officer after transition - SEC filing
RallyBio Corporation (NASDAQ: RLYB) has announced that Jonathan I. Lieber will continue to serve as Chief Financial Officer (CFO) and principal financial officer following the company’s pending merger with Avenzo Therapeutics, Inc. The transition is outlined in recent SEC filing under Form 8-K ,…
AInvest Wire · Sep 9, 2026RallyBio Corp - On Sept 8, CFO Jonathan Lieber to transition to part-time employment effective Sept 15, 2026 - SEC filing
RallyBio Corp has announced that Jonathan Lieber, the company’s chief financial officer, will transition to part-time employment effective September 15, 2026[1]. The change was disclosed in a recent SEC filing, which noted that Lieber will continue to serve in a reduced capacity, though the…
AInvest Wire · Sep 9, 2026Rallybio - Athena Countouritis to lead combined company as chair, president and CEO
AInvest Wire · Jun 1, 2026Rallybio - pre-deal Rallybio equityholders to own 2.8%, Avenzo equityholders 97.2% of combined company
AInvest Wire · Jun 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.